Neem's Hill AB Series B

CMOTEC-B · Nasdaq Stockholm · Healthcare

2.65SEK −6.0%last day

Price as of 10 September 2026

The price over the past year, with dividends: −29.7%

Performance

1 month

−14.5%

1 year

−29.7%

3 years, per year

−11.3%

5 years, per year

−37.0%

Largest fall, 3 years

−94.7%

Below the peak now

−96.1%

Volatility, 1 year

90.7%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

45.8

Dividend yield

0.0%

Return on equity

−385.3%

Net margin

−66.2%

Market value

7 m USD

Quality, value and trend

Where Neem's Hill stands against every Nordic stock today. 100 is best.

Quality16

Profitability and a sound balance sheet over time. Better than 16% of Nordic stocks.

Value4

The price measured against earnings, assets and cash flow. Better than 4% of Nordic stocks.

Trend12

The price development over the past year. Better than 12% of Nordic stocks.

Combined1

Quality, value and trend together. Better than 1% of Nordic stocks.

About Neem's Hill

Neem's Hill AB Series B is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 1 employees.

Neem's Hill AB, a medical technology company, engages in the development of patented treatment alternatives for humans and animals with cancer in Sweden and internationally. It offers IQwave, an electroporation that generates tumor-specific electrical stimulation for the treatment of solid superficial tumors of various sizes and locations. Neem's Hill AB was formerly known as Scandinavian ChemoTech AB (publ) and changed its name to Neem's Hill AB in July 2026. The company was incorporated in 2013 and is headquartered in Lund, Sweden.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis